Shares in small-cap biotech Orthocell (ASX: OCC) are edging higher today (around 4% at the time of writing) after the company released a clinical update that could prove more important than the market initially realised.
At the centre of the announcement is Remplir, Orthocell's nerve repair product, which continues to deliver strong clinical outcomes.
Image source: Getty Images
Strong treatment success rate
Orthocell reported an overall treatment success rate of 89.7% across 66 patients and 78 procedures in its ongoing real-world evidence study. That's a strong headline number with solid supporting evidence.
In motor nerve repair procedures, more than 90% of procedures resulted in functional muscle recovery. Meanwhile, in nerve decompression procedures (which are typically used to treat chronic pain, numbness, and tingling), 89% of patients experienced significant improvement or complete relief.
Importantly, these results were achieved across a broad patient group, covering different types of nerve injuries and age ranges. That kind of consistency suggests the product's effectiveness isn't limited to narrow use cases.
Just as critical is the safety profile. The study reported no post-treatment complications or adverse effects, reinforcing confidence for surgeons considering adoption.
Why this matters
For investors, the focus is on what this means commercially.
Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir. Early traction is also building in the US, including procedures within a Department of Defense hospital network.
These are all emerging signs of real value being created, which can hopefully translate into repeat usage, broader adoption, and ultimately, strong revenue growth.
Orthocell is now pushing into larger markets, with US expansion underway and Europe and the UK firmly in its sights. Regulatory approval in those regions is targeted for 2026, which could significantly expand its addressable market.
If the current clinical outcomes continue to hold and surgeon adoption keeps building, Orthocell may be moving closer to that key inflection point where a promising product becomes a scalable commercial business.
Foolish bottom line
Orthocell's latest update strengthens the case that Remplir can be widely adopted. For investors, that's a critical datapoint, and if momentum continues, this could be the early stages of a much larger growth story.
